Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $290.00

Becton, Dickinson and Company (NYSE:BDX) had its target price increased by investment analysts at Evercore ISI from $286.00 to $290.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Evercore ISI’s price target points to a potential upside of 20.14% from the company’s current price.

BDX has been the subject of a number of other research reports. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 0.1 %

Shares of NYSE BDX traded up $0.28 during trading hours on Tuesday, reaching $241.38. The stock had a trading volume of 583,089 shares, compared to its average volume of 1,420,253. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market cap of $69.76 billion, a price-to-earnings ratio of 53.10, a P/E/G ratio of 1.92 and a beta of 0.42. The business’s fifty day moving average price is $236.35 and its two-hundred day moving average price is $235.51. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.96 earnings per share. Analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 26,123,450 shares of the medical instruments supplier’s stock valued at $6,369,681,000 after acquiring an additional 195,931 shares during the period. Ameriprise Financial Inc. boosted its holdings in Becton, Dickinson and Company by 6.4% in the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after purchasing an additional 302,893 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 1.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock valued at $1,146,374,000 after purchasing an additional 87,230 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Becton, Dickinson and Company by 8.5% in the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after purchasing an additional 346,720 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in Becton, Dickinson and Company by 3.1% in the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock valued at $697,513,000 after purchasing an additional 89,157 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.